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The optimal diagnostic approach and yield for gastrointestinal bleeding (GIB) in patients with ventricular assist devices (VAD)
are unknown. We explored the etiology of bleeding and yield of upper and lower endoscopy, balloon-assisted enteroscopy, and
video capsule endoscopy in the evaluation of GIB in patients with VADs. Methods. All VAD patients with overt gastrointestinal
bleeding and drop in hematocrit from April 1, 2000 to July 31, 2008 were retrospectively reviewed. The endoscopic evaluation
of each episode was recorded. Overall yield of EGD, colonoscopy, balloon-assisted, and video capsule endoscopy were evaluated.
Results. Thirty-six bleeding episodes occurred involving 20 patients. The site of GIB was identiﬁed in 32/36 episodes (88.9%), and
the etiology of bleeding was determined in 30/36 cases (83.3%). Five VAD patients underwent VCE. The VCE exams demonstrated
a high yield with 80% of exams identifying the etiology of GIB. Endoscopic intervention was successful in 8/9 attempts. No
adverse events were recorded. Two patients required surgical intervention for GIB. Conclusion. Upper, lower, video capsule, and
balloon-assisted enteroscopies are safe and demonstrate a high yield in the investigation of gastrointestinal bleeding in VAD
patients. Medical centers caring for VAD patients should employ a standardized protocol to optimize endoscopic evaluation and
intervention.
1.Introduction
Ventricular assist devices (VAD) are an established therapy
for patients with end-stage heart failure and have been
shown to improve survival compared to optimal medical
management [1, 2]. As patients with long-term devices
survive longer, unique complications or unconventional
presentations of common medical problems, including gas-
trointestinal bleeding (GIB), are becoming more frequent.
Management algorithms in this challenging patient popu-
lation are poorly deﬁned. GIB is common in patients with
VAD. Risk factors for bleeding are complex and insuﬃciently
understood. These include concomitant use of anticoagulant
and antiplatelet agents, chronic intestinal ischemia induced
by nonpulsatile devices, and the hypothesized development
of arteriovenous malformations related to suspected Von
Willebrand’s disease. Recent evidence suggests that these
patients are at an increased risk of bleeding beyond what
would typically be expected for patients requiring anti-
coagulation for other indications [3].
VAD patients typically undergo a standard endoscopic
evaluation in the setting of acute GIB. Limited data exists
describing the yield and safety of endoscopy for the evalu-
ation of overt gastrointestinal hemorrhage in VAD patients.
In non-VAD patients, video capsule endoscopy (VCE) has
become the main diagnostic tool for the evaluation of
obscure gastrointestinal bleeding, which will aﬀect approx-
imately 5% of patients presenting with gastrointestinal
hemorrhage [4]. Capsule endoscopy has been recommended
as the third test oﬀered in the evaluation of patients with
GIB after upper endoscopy and colonoscopy are negative
[5]. The use of VCE in the evaluation of obscure-overt GI2 Gastroenterology Research and Practice
bleeding in VAD patients is limited to isolated case reports
[6–9]. We describe a cohort of VAD patients admitted for
overt gastrointestinal bleeding and report the high yield of
standard upper and lower endoscopy as well as VCE in
the diagnostic evaluation. We also describe a high rate of
success for endoscopic intervention in VAD patients. Finally,
we propose new endoscopic algorithms with an emphasis
on early VCE in the evaluation of this diﬃcult-to-manage
patient population.
2. Methods
2.1.Patients. FollowingInstitutionalReviewBoardapproval,
we performed a retrospective review of all patients who
underwent VAD placement at The Ohio State University
Medical Center. We reviewed all hospitalizations and pro-
cedure reports to identify those patients who demonstrated
anyepisodesofovertgastrointestinalbleeding.BetweenApril
1, 2000 and July 31, 2008, 162 patients were implanted
with 190 VADs. Of these, only those who were evaluated
for symptomatic gastrointestinal bleeding as deﬁned by
hematemesis, melena, and/or hematochezia with associated
decrease in baseline hematocrit were included in the data
analysis.
2.2. Endoscopic Evaluation. Patients underwent primary
evaluation with standard upper endoscopy and/or
colonoscopy within 24–48hrs upon admission to the
hospital. Upper endoscopy was performed after at least a
six-hour fast colonoscopy was carried out after a bowel
purge consisting of 4 L polyethylene glycol (Golytely).
Endoscopic procedures were performed at the bedside.
Conscious sedation was administered per standard protocol
with intravenous fentanyl and midazolam. Continuous
telemetry, blood pressure, pulse oximetry, and VAD ﬂow
rates were monitored during the procedures. In total, 33
EGDs, 15 colonoscopies, ﬁve enteroscopies (three balloon
assisted) and ﬁve VCE were performed in the evaluation of
36 episodes of bleeding.
VCE was performed using Pillcam SB (Given Imaging
Ltd, Yoqneam, Israel), according to the manufacturer’s
instructions (Given Diagnostic Imaging System, M2A cap-
sule; Given Imaging). Preparation for VCE included 2L
polyethylene glycol (Golytely) the evening before the proce-
dure and 80mg simethicone immediately prior to capsule
ingestion. Additional laxative was not given if capsule
ingestion immediately followed a negative colonoscopy. VCE
examinations were interpreted within 24 hours by one of
four gastroenterologists experienced in reading VCE exam-
inations. The videos were read at a rate of 15 frames/second.
All patients tolerated their bowel preps, conscious sedation,
and endoscopic procedures without hemodynamic or physi-
ologic complications.
2.3. Data Collection. Data were collected from our Institu-
tional Mechanical Support database and the patients’ elec-
tronic medical record. Variables including age, race, gender,
VAD device, etiology of congestive heart failure, medical
comorbidities, home medications, dates of GI bleeding and
Table 1: Demographic data in 20 VAD patients admitted for overt
GI bleeding.
Patients (no.) 20
Total number of bleeding episodes 36
Male/female 11/9
Median age (y) 56.9 (range 41–72)
Ischemic heart disease 17
Bleeding presentation
Melena 19
Hematemesis 9
Hematochezia 7
Hematemesis and hematochezia 1
Mean Hgb (g/dL) 9.01 (range 4.9–10.9)
Mean INR for pts on anticoagulation 2.29 (range 1.4–4.9)
Mean INR for pts not anticoagulated 1.4 (range 1.2–1.6)
Mean platelet count 215K/ul (range 52–630)
Mean units of blood transfused∗ 3.3 (range 0–10)
Fresh frozen plasma∗ 0.75 (range 0–8)
∗Per episode of bleeding.
associated decrease in hemoglobin/hematocrit, coagulation
parameters, blood transfusion requirement, and endoscopic
diagnosis were all recorded.
3. Results
3.1. Patients. Within the enrollment period, 20 patients
(12.3%) were identiﬁed with overt GIB, totaling 36 episodes.
These patients were treated with 27 devices including: Heart-
mate II (n = 6, Thoratec Corporation, Pleasanton, CA);
Heartmate XVE (n = 4 ) ;T h o ra t e cI V A D( n = 2); VentrAssist
(n = 2, Ventracor Limited, Chatswood, NSW, Australia);
Abiomed BVS500 (n = 6, Abiomed Corporation, Danvers,
MA) Levitronix CentriMag VAS (n = 7, Levitronix LLC,
Waltham, MA). Baseline demographics, bleeding presenta-
tion, and transfusion requirements are presented in Table 1.
Thirteen patients had one episode of GIB, whereas two
patients had two episodes, four patients had three episodes,
and one patient had seven episodes. Three patients had
a history of pre-VAD peptic ulcer disease, including one
prior GIB episode. Two patients had normal pre-VAD
screening colonoscopies. Fourteen patients were chronically
anticoagulated with warfarin. Seventeen patients were taking
aspirin and 8/17 ASA patients were taking an additional
antiplateletagent(clopidogrel,ticlopidine,ordipyridamole).
Fourteen patients were treated with either a proton pump
inhibitor or histamine receptor blocker.
3.2. Endoscopic Findings. The site of GIB was identiﬁed in
32/36 episodes (88.9%), and the etiology of bleeding was
determined in 30/36 cases (83.3%). The etiologies for
these bleeding episodes are outlined in Table 2, and the
yields for the endoscopic exams are summarized in Table 3.
The utilization of endoscopic studies by exam type is
presented in Table 4. Five VAD patients underwent VCEGastroenterology Research and Practice 3
Table 2: Endoscopic ﬁndings in 20 VAD patients admitted for 36
overt GI bleeding episodes.
Endoscopic ﬁndings Number of patients
(%)
Peptic ulcer disease 8 (22.2)
Small bowel angioectasias 6 (16.7)
Ischemic colitis 4 (11.1)
Erosive gastropathy 2 (5.6)
Ischemic gastritis 2 (5.6)
Herpes esophagitis 1 (2.8)
Esophageal ulcer 1 (2.8)
Colonic ulcer 1 (2.8)
Colon polyp 1 (2.8)
Bleeding site unknown 10 (27.8)
Patients with multiple etiologies of bleeding 3 (8.3)
Table 3: Yield of endoscopic exams.
Exam type Positive ﬁndings (%) Deﬁnite source
of bleeding (%)
EGD 28/33 (84.8) 16/33 (48.5)
Colonoscopy 10/15 (66.7) 7/15 (46.7)
Video capsule endoscopy 4/5 (80)∗ 4/5 (80)
Enteroscopy 4/5 (80) 3/5 (60)
All episodes of bleeding 32/36 (88.9) 30/36 (83.3)
∗The ﬁfth VCE exam had gastric retention and was not repeated until after
the study was concluded.
Table 4: Utilization of endoscopic studies by exam type.
Exams performed Number of patients
EGD only 8
EGD + colonoscopy 6
Colonoscopy only 1
EGD + colonoscopy + VCE 2
EGD + VCE 1
EGD + colonoscopy + enteroscopy + VCE 2
after a standard endoscopic evaluation failed to make a
diagnosis. VCE was performed on average 3.6 days after
hospital admission (range 1–7 days). The VCE exams
demonstrated a yield of 80% for identifying the etiology
of GIB. The ﬁfth VCE exam, performed on hospital day 7,
was limited by gastric retention. This patient had the VCE
repeated with endoscopic placement into the duodenum
after recurrent bleeding. VCE showed evidence of an ulcer
with active bleeding in the distal duodenum. Follow-up push
enteroscopycouldnotidentifythelesion,andthepatientwas
discharged in stable condition. The results of this positive
VCE were not included in our analysis as the exam was
performedoutsidetheinclusiondates.ThefourpositiveVCE
exams demonstrated two actively bleeding arteriovenous
malformations in the jejunum, one bleeding cecal ulcer,
and one nonbleeding submucosal jejunal mass. The cecal
ulcer demonstrated a nonbleeding visible vessel and dual
endoscopictherapywithepinephrineinjectionandhemoclip
application was successful. The patients with active bleeding
from AVMs underwent peroral single-balloon enteroscopy.
One patient had active bleeding that was distal to the
reach of the balloon enteroscope. A visceral angiogram was
performed and was normal. The patient was placed on
subcutaneous octreotide therapy with no further evidence
for GI bleeding and was discharged with supportive care
while continuing his anticoagulation. The second patient
underwent balloon enteroscopy that did not demonstrate
any lesions or active bleeding. Her anticoagulation was held
andshewasdischargedhomeonASAandpersantinetherapy
without further evidence for repeat GI hemorrhage.
Overall, endoscopic intervention in the form of
epinephrine injection, bipolar electrocautery, argon plasma
coagulation, and hemoclip application was successful in 8/9
attempts. No adverse events were recorded as a result of
the aforementioned endoscopic procedures. Two patients
required surgical intervention for acute GIB. The ﬁrst
patient underwent a right hemicolectomy for ischemic
colitis and died of refractory multiorgan failure several days
postoperatively. The second patient required a gastrotomy
and excision of an actively bleeding marginal ulcer that had
failed endoscopic therapy. She recovered postoperatively and
was discharged.
4. Discussion
As a result of the increased survival after VAD implantation,
GIB has demonstrated increasing relevance in the long-term
management of VAD patients. These individuals typically
require continuous anticoagulation and antiplatelet thera-
pies to minimize the risk of device-associated thromboem-
bolic complications or catastrophic pump failure. Man-
agement algorithms in this challenging patient population
are poorly deﬁned. Despite the increased rates of GIB,
discontinuation of anticoagulation and/or antiplatelet agents
isoftencontraindicatedduetheriskofVADthrombosis.Our
study is a comprehensive evaluation of GIB in a cohort of
VAD patients. In addition, we present a novel algorithm to
enhance the evaluation and yield of this challenging patient
population. Several authors have published their results of
successful VCE in VAD patients [6–9]. These four case
reports focus on the safety of VCE use in VAD patients,
whereas our series highlights the actual endoscopic yield,
safety, and outcomes for various modalities investigating GI
hemorrhage in this cohort.
Video capsule endoscopy has become the main diag-
nostic strategy for obscure gastrointestinal hemorrhage.
Small bowel follow-through radiographs demonstrate a low
yield (3–20%) for pathologic ﬁndings in patients with
gastrointestinal hemorrhage [10]. In addition to the low
yield, diagnostic imaging results may be compromised in
VAD patients due to the intra-abdominal placement of the
device. The superiority of capsule endoscopy was shown in a
meta-analysisofpatientswithobscureGIbleeding.Theyield
of capsule endoscopy was 56%, compared to 26% for push
enteroscopy and 3% for small bowel series [11].4 Gastroenterology Research and Practice
In our series of VAD patients with overt gastrointestinal
bleeding, multiple etiologies were responsible for their pre-
sentations, the most common of which was melena. Peptic
ulcer disease, jejunal angioectasias, and ischemic colitis were
the most common causes identiﬁed. These patients success-
fully underwent 58 endoscopic procedures, including ﬁve
VCE and three balloon-assisted enteroscopies. No adverse
events resulted from endoscopic intervention, although two
patients required surgery for ongoing hemorrhage. No
hemodynamic, electronic, or mechanical abnormalities were
observed with VCE at our institution. Not only did VCE
demonstrate a high diagnostic yield, but there was also the
opportunity for targeted endoscopic therapy. Endoscopic
intervention was successful in achieving hemostasis in 8/9
attempts, and those patients with lesions identiﬁed on VCE
were successfully treated without surgery.
GI bleeding associated with VAD patients continues to
emerge as an important postoperative comorbidity. Our
patients demonstrated their ﬁrst episode of GIB an average
of 57.9 days after device implantation (range 3–272 days).
This contradicts the REMATCH data where patients were
followed for up to 30 months without episodes of signiﬁcant
GIB. Although the cause for these diﬀerent observations is
unknown, these patients exhibit etiologies of bleeding that
are not unexpected, including peptic ulcer disease, colonic
ischemia and jejunal angioectasias. Despite these straightfor-
ward endoscopic diagnoses, numerous patients present with
multiple episodes of GIB even with antisecretory therapy
and device optimization. Thus, many VAD patients will be
expected to undergo numerous endoscopic evaluations for
GIB given their ongoing risks and medical comorbidities.
Of note, repeat standard upper and lower endoscopy may
be warranted for future episodes of bleeding, as 20% of
patients with obscure bleeding are found to have lesions
withinthereachofconventionalupperandlowerendoscopes
on subsequent examinations [12].
The timing of capsule endoscopy is paramount for
success in ﬁnding a source of bleeding [13]. Previous
investigators demonstrated a 73.3% yield for VCE in their
evaluation of obscure-overt gastrointestinal bleeding, with
an average time from admission to VCE of 4.1 days. Bresci
and colleagues reported a higher diagnostic yield for patients
with overt bleeding if the capsule study was performed
within 15 days of the acute bleeding episode [14]. Our
capsule studies were performed on average 3.6 days after
hospital admission with a yield of 80%. When VAD patients
are admitted for overt gastrointestinal bleeding, a standard-
ized protocol should be followed. Given the prevalence of
an upper digestive source of bleeding, we believe capsule
studies should be performed as early as possible. The ﬁrst
endoscopic study should be determined by an initial versus
a recurrent episode of GIB. We have developed and utilized
the algorithms shown in Figures 1 and 2. The beneﬁts of pre-
VAD screening colonoscopy in determining the etiology of
future GIB are unknown. However, given the future risk of
GIB, with the majority of cases occurring in the proximal
gastrointestinal tract, physicians should refer these patients
for a pre-VAD screening colonoscopy. In addition to the
beneﬁts of colorectal cancer screening, urgent VCE may be
Enteroscopy +
colonoscopy 
Urgent
video capsule
endoscopy
Directed
endoscopic
therapy
Success +
+
Balloon-assisted
enteroscopy
Angiography Supportive care
Failure
Surgery
−
−
Figure 1: Decision algorithm for the initial evaluation of VAD
patients with obscure-overt gastrointestinal bleeding.
Previously
negative EGD/
colonoscopy
Previously
positive
EGD/
colonoscopy
Repeat
prior
positive
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VCE
Balloon
enteroscopy
Supportive
care
+ −
Figure 2: Decision algorithm for the evaluation of VAD patients
with recurrent obscure-overt gastrointestinal bleeding.
oﬀered earlier to those patients presenting with subsequent
melena, the most common presentation among our cohort.
Such an approach would maximize the yield of diagnostic
endoscopy, including video capsule endoscopy, and lead to
earlier targeted endoscopic therapy.
Another important implication from prior VCE research
is the long-term bleeding risk after a negative exam. Mac-
donald and associates reported a signiﬁcant diﬀerence in
rebleeding between those patients with a positive capsule
examination compared to those with negative ﬁndings.
Those patients with a negative study had only an 11% rate
of recurrent bleeding, as compared to 42% for those patients
with a positive study [15]. There is no long-term data
regarding negative capsule studies in VAD patients, certainly
an area for future research.
VADs included in our study included both pulsatile
and nonpulsatile devices. Several investigators have assessed
the risks of axial versus pulsatile ﬂow and the resultant
risk of gastrointestinal hemorrhage. Crow et al. found a
bleeding rate of 63 events/100 patient years in nonpulsatile
devicerecipients[3].Thesepatients,whoalsoreceivechronic
anticoagulation with warfarin, demonstrated a much higher
bleeding rate than those patients with axial ﬂow devices.
Their analysis showed a rate of bleeding higher than that
expected by anticoagulation alone, which was shown byGastroenterology Research and Practice 5
o t h e ri n v e s t i g a t o r st ob e5 . 7 %p e ry e a r[ 16]. Narrow pulse
pressure resulting from nonpulsatile ﬂow has been posited to
lead to the development of gastrointestinal angiodysplasia.
Similar to aortic stenosis, a narrow pulse pressure may
increase intraluminal pressure and dilate mucosal veins,
leading to arteriovenous malformations [17, 18]. Further
comparison of these two populations is diﬃcult since the
decision to use speciﬁc VADs is often based upon signiﬁcant
comorbidities—and in particular the risk for bleeding or a
relative/absolute contraindication to anticoagulation.
A limitation to our study includes the retrospective data
collection. VAD patients may have presented to outside
medical facilities for gastrointestinal hemorrhage. However,
we believe this situation to be rare as our VAD patients are
always transferred to us for further management. Another
limitation to our study includes the combined data for
pulsatileaswellasnonpulsatiledevices.Asmentionedabove,
VAD selection is carefully weighed on patients’ absolute or
relative contraindications to aggressive anticoagulation. All
patients are maintained on prophylaxis with daily aspirin.
Our intent was not to ascertain the bleeding risk attributable
to these diﬀerences in device type or medication regimen,
but rather to assess the endoscopic yield and safety for
these patients presenting with GIB. We believe these data are
applicable to all VAD patients with GI bleeding as one would
not alter the endoscopic workup based on VAD device type.
5. Conclusions
GI bleeding is relatively common in VAD patients with vary-
ing etiologies. Traditional endoscopic procedures including
EGD, colonoscopy, and push enteroscopy can be safely
performed in this patient population. In addition, balloon
enteroscopy and VCE are safe and valid interventions to
evaluate GIB in this cohort. The early use of VCE has
a high diagnostic yield in the VAD patient population.
Our multidisciplinary approach has produced high yield
results with an opportunity to provide early endoscopic
therapy as well as minimize long-term morbidity. Given
the longer survival, need for long-term anticoagulation and
antiplatelet therapy, and increased incidence of GIB, we
believe any medical center providing care for those with
VAD should implement a standardized protocol regarding
the management of gastrointestinal hemorrhage. As a result,
standardandcapsuleendoscopywillbeperformedasearlyas
possible to maximize the diagnostic yield and oﬀer directed
endoscopic therapy.
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